

IN THE CLAIMS

1. (canceled)

2. (original) A method of screening for therapeutic agents useful in the treatment of a disease selected from cardiovascular diseases, CNS disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of

i) determining the activity of a FPRL2 polypeptide at a certain concentration of a test compound or in the absence of said test compound,

ii) determining the activity of said polypeptide at a different concentration of said test compound.

3. (original) A method of screening for therapeutic agents useful in the treatment of a disease selected from cardiovascular diseases, CNS disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases in a mammal comprising the steps of

i) determining the activity of a FPRL2 polypeptide at a certain concentration of a test compound,

ii) determining the activity of a FPRL2 polypeptide in the presence of a compound known to be a regulator of a FPRL2 polypeptide.

4-25. (canceled)

26. (new) The method of claim 2, wherein the FPRL2 polypeptide is in a cell.

27. (new) The method of claim 26, wherein the cell is *in vitro*.

28. (new) The method of claim 2, wherein the FPRL2 polypeptide is in a cell-free system.

29. (new) The method of claim 3, wherein the FPRL2 polypeptide is in a cell.

30. (new) The method of claim 29, wherein the cell is *in vitro*.

31. (new) The method of claim 3, wherein the FPRL2 polypeptide is in a cell-free system.